Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

9.880 -0.660 (-6.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Mersana Misses Fiscal Q2 Revenue Target
Via The Motley Fool
A Look at Mersana Therapeutics's Upcoming Earnings Report
 
Via Benzinga
What's going on in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Thursday's session: gap up and gap down stocks
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
An Overview of Mersana Therapeutics's Earnings
 
Via Benzinga
Earnings Scheduled For November 13, 2024
 
Via Benzinga
Earnings Preview For Mersana Therapeutics
 
Via Benzinga
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
 
Via Benzinga
Earnings Scheduled For August 13, 2025
 
Via Benzinga
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Top movers in Thursday's after hours session
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Earnings Scheduled For March 3, 2025
 
Via Benzinga
A Preview Of Mersana Therapeutics's Earnings
 
Via Benzinga
What To Know About Citigroup's Upgrade of Mersana Therapeutics
 
Via Benzinga
Earnings Scheduled For May 15, 2025
 
Via Benzinga
A Preview Of Mersana Therapeutics's Earnings
 
Via Benzinga
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast cancer. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
MRSN Stock Earnings: Mersana Therapeutics Misses EPS, Misses Revenue for Q2 2024
MRSN stock results show that Mersana Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024
MRSN stock results show that Mersana Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday. 
Via Benzinga
Topics Stocks
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune. 
Via InvestorPlace
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant... 
Via PressReach
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.